Modeling and validating Bayesian accrual models on clinical data and simulations using adaptive priors

Statistics in Medicine

Volumn 34, Issue 4, 2015, Pages 613-629

  Jiang, Yu ^a   Simon, Steve ^d,e   Mayo, Matthew S ^a,c   Gajewski, Byron J ^a,b,c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^d P Mean Consulting   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Clinical trials; Data monitoring committee; Hedging prior; Objective prior; Patient accrual

Indexed keywords

AMFEBUTAMONE;

BAYES THEOREM; BIOSTATISTICS; CLINICAL TRIAL (TOPIC); COLORECTAL NEOPLASMS; COMPUTER SIMULATION; HUMAN; PATIENT SELECTION; PROCEDURES; SAMPLE SIZE; SMOKING CESSATION; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME;

BAYES THEOREM; BIOSTATISTICS; BUPROPION; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; HUMANS; MODELS, STATISTICAL; PATIENT SELECTION; SAMPLE SIZE; SMOKING CESSATION; TIME FACTORS;

EID: 84920377464     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6359     Document Type: Article

References (25)

1. Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, Sargent DJ, Benedetti J, DL Wickerham, Djulbegovic B, Slingluff CL Jr. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clinical Trials 2010; 7(4):312-321.
2. Philipson TJ, Mozaffari E, Maclean JR. Pharmacy cost sharing antiplatelet therapy utilization and health outcomes for patients with acute coronary syndrome. American Journal of Managed Care 2010; 16(4):290-297.
3. Parreco LK, DeJoice RW, Massett HA, Padberg RM, Thakkar SS. Power of an effective clinical conversation: improving accrual onto clinical trials. Journal of Oncology Practice 2012; 8(5):282-286.
4. Barnard KD, Dent L, Cook A. A systematic review of models to predict recruitment to multicentre clinical trials. BMC Medical Research Methodology 2010; 8:63.
5. Zhang X, Long Q. Modeling and prediction of subject accrual and event times in clinical trials: a systematic review. Clinical Trials 2012; 9:681-688.
6. Carter RE. Application of stochastic processes to participant recruitment in clinical trials. Controlled Clinical Trials 2004; 25:429-436.
7. Carter RE, Sonne SC, Brady KT. Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study. BMC Med Res Methodol 2005; 5:11.
8. Anisimov VV, Fedorov VV. Modelling prediction and adaptive adjustment of recruitment in multicentre trials. Statistics in Medicine 2007; 26(27):4958-4975.
9. Bakhshi A, Senn S, Phillips A. Some issues in predicting patient recruitment in multi-centre clinical trials. Statistics in Medicine 2013; 32(30):5458-5468.
10. Abbas I, Rovira J. Clinical trial optimization: Monte Carlo simulation Markov model for planning clinical trials recruitment. Contemporary Clinical Trials 2007; 28:220-231.
11. Haidich AB, Ioannidis JP. Determinants of patient recruitment in a multicenter clinical trials group: trends seasonality and the effect of large studies. BMC Medical Research Methodology 2001; 1:4.
12. Zhang X, Long Q. Joint monitoring and prediction of accrual and event times in clinical trials. Biometrical Journal 2012; 54(6):735-749.
13. Gajewski BJ, Simon SD, Carlson SE. Predicting accrual in clinical trials with Bayesian posterior predictive distributions. Statistics in Medicine 2008; 27(13):2328-2340.
14. Casella G, Berger RL. Statistical Inference (2nd edn) Duxbury Press: Pacific Grove, CA, 2002; p100.
15. van der Wouden JC, Blankenstein AH, Huibers MJ, van der Windt DA, Stalman WA, AP Verhagen . Survey among 78 studies showed that Lasagna's law holds in Dutch primary care research. Journal of Clinical Epidemiology 2007; 60(18):819-824.
16. Williams HC, Seed P. Inadequate size of negative clinical trials in dermatology. British Journal of Dermatology 1993; 128(3):317-326.
17. Breau RH, Carnat TA, Gaboury I. Inadequate statistical power of negative clinical trials in urological literature. Journal of Urology 2006; 176(1):263-266.
18. Jayakaran C, Saxena D, Yadav P. Negative studies published in Indian medical journals are underpowered. Indian Pediatrics 2011; 48(6):490-491.
19. Keen HI, Pile K, Hill CL. The prevalence of underpowered randomized clinical trials in rheumatology. The Journal of Rheumatology 2005; 32(10):2083-2088.
20. Ibrahim JG, Chen MH. Power prior distributions for regression models. Statistical Science 2000; 15(1):46-60.
21. Duan Y, Ye K, Smith EP. Evaluating water quality using power priors to incorporate historical information. Environmetrics 2006; 17:95-106.
22. Neuenschwander B, Branson M, Spiegelhalter DJ. A note on the power prior. Statistics in Medicine 2009; 28(28):3562-3566.
23. Hobbs BP, Carlin BP, Mandrekar SJ, Sargent DJ. Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics 2011; 67:1047-1056.
24. Jonhnson NL, Kotz S, Balakrishnan N. Chapter 25 of Continuous Univariate Distributions (2nd Edition), Vol.2. Wiley: New York, 1995.
25. Gajewski BJ, Simon SD, Carlson SE. On the constant existence of constant rates in clinical trials and direction for future research. International Journal of Statistics and Probability 2012; 1(2):43-46.